Comparative Pharmacology
Head-to-head clinical analysis: MPI INDIUM DTPA IN 111 versus STRONTIUM CHLORIDE SR 89.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MPI INDIUM DTPA IN 111 versus STRONTIUM CHLORIDE SR 89.
MPI INDIUM DTPA IN 111 vs STRONTIUM CHLORIDE SR-89
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Indium In-111 DTPA is a radiopharmaceutical that emits gamma radiation, used for imaging. DTPA chelates indium-111 and, after administration, distributes in the extracellular fluid and is cleared by glomerular filtration, allowing cisternography and renal imaging.
Strontium-89 is a calcium mimetic that localizes to bone, particularly areas of increased osteoblastic activity, emitting beta radiation that causes DNA damage and cell death in metastatic tumor cells.
Adult: 18.5 MBq (0.5 mCi) administered intravenously as a single dose for renal imaging.
148 MBq (4 mCi) intravenously over 1-2 minutes, single dose. Repeat after 3-6 months if needed.
None Documented
None Documented
Terminal half-life: 2.5-4.0 hours (plasma); prolonged in renal impairment.
Terminal elimination half-life: 50.5 days (range 33–65 days). Reflects slow clearance from bone; clinical effect persists due to long skeletal retention.
Renal: 90% within 24 hours via glomerular filtration; minimal biliary/fecal (<5%).
Primarily renal (urinary) excretion; approximately 50-80% of absorbed dose eliminated via urine over 7 days. Fecal elimination is negligible (<5%).
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical